30/04/2026
Ketamine has FDA clearance. Psilocybin is still Schedule I. MDMA-assisted therapy was rejected by the FDA last year — and yet your patients are coming in having watched the documentaries, read the profiles, and in some cases, already tried it.
The clinical problem isn't whether these therapies have merit. It's that media literacy and clinical evidence are diverging rapidly, and you're in the middle.
How do you acknowledge what the data actually supports? How do you counsel patients who've self-administered, or how to stay credible when your patient knows more about the headlines than you'd like?
3-minute read: https://tr.ee/sjufvS